Samuel J Klempner
Overview
Explore the profile of Samuel J Klempner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
4096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rajdev L, King G, Lieu C, Cohen S, Pant S, Uboha N, et al.
JCO Precis Oncol
. 2025 Mar;
9:e2400489.
PMID: 40048671
Purpose: Circulating tumor DNA (ctDNA) is an emerging tool in the evaluation of GI cancers. Challenges remain in defining its utility and role as a primary end point in therapeutic...
2.
3.
Gandara D, Agarwal N, Gupta S, Klempner S, Andrews M, Mahipal A, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39915003
Background: There is uncertainty around clinical applicability of tumor mutational burden (TMB) across cancer types, in part because of inconsistency between TMB measurements from different platforms. The KEYNOTE 158 trial...
4.
Esfahani S, Ma L, Krishna S, Ma H, Raheem S, Shuvaev S, et al.
Sci Transl Med
. 2024 Dec;
16(777):eadn7218.
PMID: 39661705
Patients with advanced gastric cancer (GCa) have limited treatment options, and alternative treatment approaches are necessary to improve their clinical outcomes. Because fibrin is abundant in gastric tumors but not...
5.
Lander E, Aushev V, Huffman B, Hanna D, Dutta P, Ferguson J, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400288.
PMID: 39642325
Purpose: After neoadjuvant therapy (NAT) and surgery, up to one third and one half of patients with esophagogastric adenocarcinoma with a pathologic complete response (pCR; tumor regression grade 0 [TRG-0])...
6.
Klempner S, Sonbol M, Wainberg Z, Uronis H, Chiu V, Scott A, et al.
J Clin Oncol
. 2024 Oct;
43(3):339-349.
PMID: 39432867
Purpose: The outcomes of anti-PD-1 agents plus fluoropyrimidine/platinum in frontline advanced gastroesophageal adenocarcinomas (aGEAs) remain poor. We investigated the safety, tolerability, and activity of fluoropyrimidine/oxaliplatin and tislelizumab with the DKK1-neutralizing...
7.
Strickland M, Klempner S
Med
. 2024 Oct;
5(10):1191-1193.
PMID: 39395400
Li et al. present data from a randomized frontline phase II trial in HER2+ gastroesophageal cancers exploring dual targeting of HER2 with HLX22 (a novel HER2-specific antibody) with HLX02 (a...
8.
Shitara K, Shah M, Lordick F, Van Cutsem E, Ilson D, Klempner S, et al.
N Engl J Med
. 2024 Sep;
391(12):1159-1162.
PMID: 39282934
No abstract available.
9.
Park H, Klempner S, Chao J, Wainberg Z, Lukanowski M, Chenji S, et al.
Front Oncol
. 2024 Aug;
14:1419338.
PMID: 39206150
Introduction: The aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or...
10.
Zhao J, Ong C, Srivastava S, Chia D, Ma H, Huang K, et al.
Gastroenterology
. 2024 Aug;
167(7):1384-1398.e4.
PMID: 39147169
Background & Aims: Peritoneal metastasis (PM) in gastric cancer (GC) is associated with poor prognosis and significant morbidity. We sought to understand the genomic, transcriptomic, and tumor microenvironment (TME) features...